16.20
16.20 (0%)
As of Feb 14, 2025
Liquidia Corp [LQDA]
Source:
Company Overview
Liquidia Corp is a biopharmaceutical company focused on the development, manufacture, and commercialization of products that address unmet patient needs, with current focus directed towards rare cardiopulmonary diseases such as pulmonary arterial hypertension (“PAH”) and pulmonary hypertension associated with interstitial lung disease (“PH-ILD”).
| Country | United States |
| Headquarters | morrisville, north carolina |
| Phone Number | 919.328.4400 |
| Industry | |
| CEO | Roger A. Jeffs, Ph.D. |
| Website | www.liquidia.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $14 |
| Operating Profit | $-121.3 |
| Net Income | $-130.4 |
| Net Cash | $92.8 |
Profit Ratios
| Gross Margin | $8.1 |
| Operating Margin | -866.6 |
| Profit as % of Revenues | -6.2% |
| Profit as % of Assets | -74.8% |
| Profit as % of Stockholder Equity | -168.7% |
Management Effectiveness
| Return on Equity | -168.7% |
| Return on Assets | -56.6% |
| Turnover Ratio | 8% |
| EBITA | $-121.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $230.3 |
| Total Liabilities | $153 |
| Operating Cash Flow | $-93.4 |
| Investing Cash Flow | $-8.4 |
| Financing Cash Flow | $194.7 |
